Diligence memo · auto-generated · as of July 2, 2026
JW (Cayman) Therapeutics Co. Ltd
JW (Cayman) Therapeutics Co. Ltd looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
JW (Cayman) Therapeutics Co. Ltd operates in Biotechnology, based in Shanghai.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
JW (Cayman) Therapeutics Co. Ltd has raised $106M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $106M on 2020-06-30.
Most recent recorded round closed around 2020-06-30.
Valuation (modeled)modeled
Provath models JW (Cayman) Therapeutics Co. Ltd at approximately $4.4B (range $478M–$9.5B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.03× the median modeled value of Series D+ Biotechnology companies in 2019–2021 (58 peers) — value vs value, same stage and era. Within the normal band (103% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 6.0 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 91% of Biotechnology peers (4293 compared).
Modeled value ranks above 99% of those peers.
Closest niche peers: Sarepta Therapeutics, Inc., Asklepios BioPharmaceutical, Inc., Affinivax, Inc., Sonoma Biotherapeutics, Inc., Instil Bio, Inc..
Peoplefiled
14 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.